Related Experiment Video

Updated: Jun 4, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy

Benjamin Meder1,2,3, Caroline J Coats4, Leslie A Leinwand5,6

  • 1Department of Cardiology, Angiology and Pulmonology, Institut für Cardiomyopathien Heidelberg, University of Heidelberg, INF 410, Im Neuenheimer Feld 410, Heidelberg 69120, Germany.

European Journal of Heart Failure
|March 2, 2026
PubMed

Insights

Hypertrophic cardiomyopathy (HCM), a common genetic heart condition, requires updated guidance. This consensus document offers expert consensus on diagnosis, risk stratification, and treatment, including novel therapies for HCM management.

Area of Science:

  • Cardiology
  • Genetics
  • Internal Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease.
  • It is a leading cause of heart failure, arrhythmia, and sudden cardiac death.
  • Existing guidelines require further clinical interpretation and guidance.

Purpose of the Study:

  • To provide a consensus document on Hypertrophic Cardiomyopathy (HCM).
  • To address areas needing further clinical guidance beyond current guidelines.
  • To consolidate expert opinion on diagnosis, risk stratification, and management of HCM.

Main Methods:

  • Multidisciplinary expert panel review.
  • Alignment with European Society of Cardiology (ESC) and American Heart Association/American College of Cardiology (AHA/ACC) guidelines.
  • Inclusion of phenotypic classification, diagnostic strategies, and therapeutic pathways.

Main Results:

  • Comprehensive review of diagnostic strategies, including imaging and genetic testing.
  • Detailed outline of pharmacologic treatments (e.g., beta-blockers, myosin inhibitors) and septal reduction therapies.
  • Discussion of management for associated conditions like atrial fibrillation and hypertension.

Conclusions:

  • The consensus addresses current controversies in HCM management.
  • It provides guidance on genotype-positive/phenotype-negative individuals and exercise recommendations.
  • Future directions include gene therapy, precision medicine, AI, and novel biomarkers for HCM.

Keywords:
Consensus recommendationsHypertrophic cardiomyopathyMyosin inhibitorsNon-obstructive HCMObstructive HCMSeptal reduction therapy

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...